Adherium
Digital health solutions for respiratory conditions including asthma and copd.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | AUD4.0m | Post IPO Equity |
| Total Funding | 000k | ||
| AUD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (82 %) | 32 % | 504 % | (74 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (381 %) | (3156 %) | (2087 %) | (302 %) | (1203 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (514 %) | (3750 %) | (2122 %) | (309 %) | (1216 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 178 % | 1366 % | 1111 % | 148 % | 493 % |
Source: Company filings or news article
Related Content
Adherium Limited is an international company specializing in Respiratory eHealth, which means they focus on using technology to help manage respiratory diseases like asthma and COPD (Chronic Obstructive Pulmonary Disease). The company creates advanced digital solutions to improve patient adherence to medication and provide remote monitoring. This helps patients, healthcare providers, and insurance companies manage respiratory conditions more effectively.
Adherium operates in the healthcare technology market, specifically targeting patients with respiratory diseases, healthcare providers, and payers (insurance companies). Their business model revolves around developing and selling smart inhaler devices and associated software that tracks and reports medication usage. These devices are designed to ensure patients take their medication correctly and consistently, which is crucial for managing chronic respiratory conditions.
The company generates revenue by selling these smart inhaler devices and offering subscription-based services for their data management solutions. They have received clearance from the U.S. Food and Drug Administration (FDA) for use with inhalation devices from major pharmaceutical companies like AstraZeneca, which adds credibility and expands their market reach.
Adherium's management team brings extensive experience from various sectors, including medical, technology, and manufacturing, ensuring they have the expertise to drive the company's strategic goals. They are committed to attracting top talent and fostering a high-performance culture to deliver excellent results for patients, customers, and shareholders.
In summary, Adherium Limited is a leader in digital respiratory health solutions, focusing on improving medication adherence and providing remote monitoring to enhance patient outcomes and reduce healthcare costs.
Keywords: Respiratory eHealth, smart inhalers, asthma management, COPD, digital health, remote monitoring, patient adherence, healthcare technology, FDA clearance, data management.